Explore the forefront of interventional cardiology innovation with the Jon DeHaan Foundation Award competition, featuring pioneering solutions for valvular heart disease and mechanical support. This session highlights novel devices such as TriFlo for tricuspid regurgitation, the extravascular ventricular assist device (eVAD System), and the first-in-human experience...

Watch this EuroPCR 2026 session to better understand how lesion preparation strategies can be optimised in complex PCI using directional scoring balloon technology with DK Score Pro.

Clinical evidence is reviewed, including insights from the SCORE CHINA registry, alongside practical considerations for integrating this approach into routine...

Innovations in heart failure care are transforming patient management, from real-time, non-invasive congestion monitoring to advanced mechanical support systems. This session presents the Anusar congestion assessment tool, early clinical data on the NuPulse intravascular ventricular assist system for ambulatory support, and explores AI-driven voice biomarker technology...

Management of pulmonary embolism is increasingly shifting toward interventional strategies, where timing, patient selection and procedural expertise play a central role in improving outcomes.

Large-bore thrombectomy is examined as a key option within contemporary PE treatment, focusing on when intervention is most appropriate and how to optimise...

Explore the global challenge of hypertension, affecting one in three adults, and the strategies for screening, diagnosis, and management, including lifestyle modifications, pharmacotherapy, and device-based treatments, as outlined by Sofie Brouwers.

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Jonathan Curio provides his take on TRISCEND II trial results presented by Vinod H. Thourani at ACC.26 in New Orleans.

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

In this article, Jens Erik Nielsen-Kudsk reviews the evolution of left atrial appendage closure, from early trials such as PROTECT‑AF to recent evidence including CHAMPION‑AF, and discusses its expanding role in stroke prevention for atrial fibrillation.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...